Online inquiry

IVTScrip™ mRNA-Human ARL8B, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK23251MR)

This product GTTS-WK23251MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ARL8B protein. This product can be used in Endothelial cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_018184.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 55207
UniProt ID Q9NVJ2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ARL8B, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK23251MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK16645MR IVTScrip™ mRNA-Human ALYREF, (Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ALYREF
GTTS-WK11674MR IVTScrip™ mRNA-Human ADTRP, (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ADTRP
GTTS-WK13441MR IVTScrip™ mRNA-Human ADGRG1, (Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ADGRG1
GTTS-WK21723MR IVTScrip™ mRNA-Human ARID2, (Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ARID2
GTTS-WK24967MR IVTScrip™ mRNA-Human ARF5, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ARF5
GTTS-WK21778MR IVTScrip™ mRNA-Human ARRDC1-AS1, (Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ARRDC1-AS1
GTTS-WK6843MR IVTScrip™ mRNA-Human CD133, (Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CD133
GTTS-WK16036MR IVTScrip™ mRNA-Human alpha-Sarcoglycan, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA alpha-Sarcoglycan
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW